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Abstract 
Scope 
People who carry the apolipoprotein E4 (APOE4) SNP have an increased risk of 
cardiovascular disease (CVD). Fish-oil supplementation may help in the prevention of CVD, 
though inter-individual differences in the response to n-3 PUFAs have been observed. We 
aimed to assess the impact of APOE genotype on peripheral blood mononuclear cell (PBMC) 
whole genome gene expression at baseline and following a fish-oil intervention. 
 
Methods and results 
Participants received 6 months of fish-oil supplementation containing 1800 mg of 
eicosapentaenoic acid and docosahexaenoic acid per day. APOE genotype and PBMC whole 
genome gene expression before and after supplementation were measured. We characterized 
the differences in gene expression profiles in carriers of APOE4 (N=8) compared to non-
carriers (N=15). At baseline, 1320 genes were differentially expressed and the fish-oil 
supplementation differentially regulated 866 genes between APOE4 carriers and non-carriers. 
Gene set enrichment analysis showed that carriers had a higher gene expression of cholesterol 
biosynthesis and interferon (IFN) signaling pathways. Fish-oil supplementation reduced 
expression of IFN-related genes in carriers only.  
 
Conclusion 
The increased expression of IFN signaling and cholesterol biosynthesis pathways might 
explain part of the association between APOE4 and CVD. Fish-oil supplementation may 
particularly benefit APOE4 carriers by decreasing expression of IFN-related genes. 
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Introduction 
Apolipoprotein E (APOE) is part of several types of lipoproteins including VLDL, HDL and 
chylomicrons [1]. Three major isoforms exist: APOE2, APOE3 and APOE4, which have 
allele frequencies of 6%, 15% and 78% respectively [2]. Large meta-analyses have shown that 
carriers of APOE4 have a modestly increased risk of coronary heart disease [3, 4] and stroke 
[5] compared with individuals with the APOE3/APOE3 genotype, though the magnitude of 
this finding differs between studies and it is not always significant [4]. Furthermore APOE4 is 
associated with increased levels of LDL cholesterol [4-6] and triglycerides [7] in the plasma.  
For prevention of CVD, the European Society of Cardiology recommends two fatty fish-
containing meals a week [8]. A meta-analysis of randomized controlled trials showed that 
supplementary n-3 polyunsaturated fatty acids (PUFAs) decreases the risk of CVD [9]. 
However, this positive impact on CVD is not reported consistently; several studies find no 
association between n-3 PUFA supplementation and CVD risk [10]. Furthermore, inter-
individual differences in the response to n-3 PUFAs have been observed. This inter-individual 
variability may, in part, be caused by genetic factors [11].  
Several studies have shown that APOE genotype influences the plasma lipid response to fish-
oil supplementation. Minihane et al. 2000 [12] found a significant increase in total cholesterol 
and a trend toward a reduction in HDL-Cholesterol in APOE4 carriers relative to 
APOE3/APOE3 subjects after fish-oil supplementation. In line with this, Olano-martin et al. 
2010 [13] found increased total cholesterol concentrations in APOE4 carriers in response to 4 
weeks docosahexaenoic acid (DHA) supplementation. Caslake et al 2008 [14] found the 
greatest decrease in plasma triglyceride concentration in APOE4 men after fish-oil 
supplementation.  
We previously showed that 6 months fish-oil supplementation decreased gene expression of 
genes involved in inflammatory and atherogenic pathways in peripheral blood mononuclear 
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cells (PBMCs) [15]. PBMCs are a subpopulation of circulating immune cells mainly 
consisting of monocytes and lymphocytes. These circulating immune cells are important 
players in the pathogenesis of CVD, especially atherosclerosis, and, therefore, are a suitable 
target for studying inflammatory and CVD mechanisms [16]. APOE genotype has been 
shown to affect immune cell response [17-19]. For example, mice monocytes/macrophages 
showed an increased inflammatory response when transfected to produce human APOE4 
compared to APOE3 [17]. Moreover, signaling via the APOE receptors promotes conversion 
of macrophages from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype [18], 
which may be decreased in APOE4 carriers because of the lower APOE concentrations that 
are observed with APOE4 [19]. From these results, it is thought that the altered inflammatory 
response of APOE4-expressing monocytes/macrophages may contribute to the higher CVD 
risk observed in APOE4 carriers. 
By measuring PBMC whole genome gene expression with microarrays and combining this 
with APOE genotyping, we are able to unbiasedly study genotype-specific phenotype effects.   
In this study, we aimed to gain more insight in the pathways affected by APOE4 and the 
effect of fish-oil supplementation on these pathways by studying gene-diet interactions 
between APOE4 and fish-oil supplementation on whole genome gene expression. To do this, 
we conducted a secondary retrospective analysis according to APOE4 carrier status of the 
above-mentioned study [15, 20]. Firstly, we studied the effect of APOE4 on whole genome 
PBMC gene expression at baseline and, secondly, we studied how APOE4 influences the 
effects of 6 months of fish-oil supplementation on gene expression. 
 
Material and methods 
Study design 
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This study is a secondary retrospective analysis of a randomized, double-blind, placebo-
controlled trial conducted by van de Rest et al. (2008) [20] that was originally designed to 
examine the effects of 6 months fish-oil supplementation on cognitive performance in 302 
participants aged ≥ 65 years.  In this secondary analysis, we examine differences in whole 
genome gene expression between APOE4 carriers and APOE4 non-carriers before and 
following the fish-oil intervention. Microarray data was available in 23 subjects from the high 
dose fish-oil group [15], with RNA available in 92 participants. To validate findings of the 
microarray analyses, we performed targeted QPCR measurements in these 92 participants 
Design and methods of the original study were described in detail previously [20]. Briefly, 
participants were randomly allocated to receive a daily dose of fish-oil containing either 1800 
mg or 400 mg eicosapentaenoic acid (EPA) and DHA, or a placebo oil (high-oleic sunflower 
oil (HOSF)) for 26 weeks. The high daily dose of fish oil provided 1093 ± 17 mg EPA and 
847 ± 23 mg DHA, and the low daily dose provided 226 ± 3 mg EPA and 176 ± 4 mg DHA. 
The oils were administered in 6 soft gelatin capsules daily, each of which contained 900 mg 
oil and 2.7 mg tocopherol as antioxidant (Banner Pharmacaps Europe BV, Tilburg, 
Netherlands).  
Participants were recruited according to the following exclusion criteria: current or recent (<4 
weeks) use of fish-oil supplements or intake of fish >4 times/week or >800 mg fish-oil/d from 
fish as estimated by using a fish-consumption questionnaire, serious liver disease, 
consumption of >4 glasses of alcohol-containing beverages per day, unable to participate as 
judged by the responsible medical physician, allergy to fish or fish-oil, swallowing problems, 
or participation in another clinical trial <2 mo before the start of the trial or at the same time. 
Cognitive exclusion criteria were also used and were described previously [20]. Additionally, 
compliance with capsule use during a 2-week placebo run-in period had to be ≥80% on the 
basis of self-report. All participants gave written informed consent to participate in the study 
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and the study protocol was approved by the Medical Ethical Committee of Wageningen 
University, Wageningen, the Netherlands. The study was registered at clinicaltrials.gov as 
NCT00124852. 
Blood sampling and PBMC isolation 
Fasting venous blood samples were collected at baseline and after 26 weeks of intervention. 
Plasma free fatty acids and triglycerides were measured by gas-liquid chromatography, and 
C-reactive protein (CRP) concentrations were determined from measurements of high-
sensitivity CRP (hsCRP). For PBMC isolation, 4 mL blood was collected into Becton 
Dickinson Vacutainer Cell Preparation Tubes with sodium citrate. PBMCs were isolated 
immediately after blood collection according to the manufacturer's instructions. For APOE 
genotyping, a second blood sample was collected into a 4.5-mL EDTA Vacutainer and stored 
at -80°C. 
APOE genotyping 
APOE genotyping was done by the PCR-based restriction fragment length polymorphism 
method and restriction enzyme digestion with HhaI [21]. We retrospectively determined 
APOE genotype in 301 of the participants of the original study.  
RNA extraction and microarray 
RNA extraction and microarray methods were previously described by Bouwens et al. [15] 
and data can be found in Gene Expression Omnibus under accession number GSE12375. We 
reanalyzed the data using the current gene definitions (NuGOHs1a520180_Hs_ENTREZG 
MBNI custom CDF version 19.0.0) and grouped the samples based on the APOE genotyping 
results (Supporting Information table S1). 
Microarray analysis was performed on baseline samples and on samples after 26 weeks of 
intervention, using human whole-genome NuGO GeneChip arrays designed by the European 
Nutrigenomics Organization and manufactured by Affymetrix (Affymetrix Inc, Santa Clara, 
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CA). Microarrays were analyzed using MADMAX (Management and Analysis Database for 
Multiplatform Microarray Experiments) [22]. Expression values were normalized using the 
RMA (robust multichip average method) [23]. Genes with normalized expression values >20 
on at least 5 arrays were defined as expressed and selected for further analysis. Expression 
values were log2-transformed. LIMMA [24] was used to calculate P-values and false 
discovery rate (FDR) q-values for each gene using t-tests with Bayesian correction. At 
baseline, genes were defined as differentially expressed between APOE4 carriers and non-
carriers if they had P-values < 0.05. The differences in response to fish-oil supplementation 
were calculated using the individual log ratios. Differences in genes expression changes 
between APOE4 carriers and non-carriers were defined as significantly different if they had P-
values < 0.05. 
Pathway analysis and upstream transcription regulators analyses were performed using 
QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, 
www.qiagen.com/ingenuity). We also performed pathway analysis using gene set enrichment 
analysis (GSEA; http://www.broad.mit.edu/gsea) [25]. Briefly, genes were ranked based on 
the t-statistic and analyzed for over- or underrepresentation in predefined gene sets. Gene sets 
were derived from Biocarta, KEGG, Reactome and Wikipathways pathway databases. 
Genesets with a false discovery rate < 0.1 were considered significantly enriched 
(Supporting Information tables S2-S5). 
QPCR  
For qPCR, RNA was available of PBMCs of 92 participants of which 31 were carriers and 61 
were non-carriers of APOE4. RNA was reverse transcribed using a cDNA synthesis kit 
(RevertAid First Strand cDNA Synthesis kit, Thermo Scientific, Leusden, the Netherlands) 
and analyzed by qPCR (SensiMix SYBR No-ROX, Bioline, London, UK) on a CFX384 Real-
Time System (C1000 Thermal Cycler, Biorad, Veenendaal, The Netherlands). qPCR data 
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were normalized using the RPLP0 housekeeping gene. Genes for qPCR were selected from 
the differentially expressed pathways between APOE4 carriers and non-carriers. Genes 
needed to be differently expressed between APOE4 carriers and non-carriers and have an 
expression value above 200. Primers sequences are shown in Table 1. 
Statistics 
Statistical analysis of subject characteristics and qPCR findings was performed using IBM 
SPSS Statistics, Version 22.0.0.1. A two-sided P < 0.05 was considered significant. Subject 
characteristics were reported as mean ± sd. Baseline characteristics of APOE4 carrier and 
non-carrier groups were compared using independent t-tests. QPCR results were analyzed 
using independent t-tests. 
Power calculations were performed retrospectively for the HMGCS1 gene. Power was 
calculated to be 83%, using the mean expression values and standard deviations as observed 
(218.7 and 184.8 for APOE4 carriers; and 28.2 and 23.5 for APOE4 non-carriers).  
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Results 
Participant characteristics 
The original study consisted of 302 participants. Here, we focused on a subgroup of 
participants who received 1800 mg fish-oil and on whom PBMC whole genome gene 
expression microarray analysis was performed (N=23). APOE genotyping showed that 8 of 
the 23 participants were carriers of APOE4. Baseline characteristics of carriers and non-
carriers are presented in Table 2. We found no differences in any parameters between the 
groups. Participants received daily fish-oil supplementation containing 1800 mg of EPA and 
docosahexaenoic acid (DHA) for 6 months. We found no difference in the changes in any 
parameters between APOE4 carriers and non-carriers (Table 2).  
Baseline 
To determine the effects of APOE4 on gene expression, baseline expression profiles were 
compared between APOE4 carriers and non-carriers. Of the 13027 genes found to be 
expressed, 1320 genes were differentially expressed between carriers and non-carriers of the 
APOE4 SNP at P < 0.05 (Figure 1). No genes showed an FDR q < 0.05. 
To gain further insight into the biological processes affected by APOE4, we performed 
pathway analysis using Ingenuity Pathway Analysis on the set of differentially expressed 
genes at baseline. Figure 2 shows the top 10 pathways that were enriched in the comparison 
of APOE4 carriers and non-carriers. Several of these pathways were related to either 
cholesterol biosynthesis or interferon (IFN) signaling. Furthermore, GSEA showed several 
gene sets related to cholesterol biosynthesis or IFN signaling as upregulated. (Supporting 
Information table S2). 
Further inspection of the function of the genes related to cholesterol biosynthesis, showed that 
many of these genes are encoding enzymes involved in de novo synthesis of cholesterol. 
These genes were found to be more highly expressed in APOE4 carriers than in non-carriers. 
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Genes involved in cholesterol uptake (LDLR and CD36) and efflux (ABCA1, ABCG1 and 
SCARB1) showed no difference in expression in APOE4 carriers compared to non-carriers. 
We observed a higher expression of genes involved in IFN signaling in carriers compared to 
non-carriers of APOE4. These genes included IFN (alpha, beta and omega) receptor 1 
(IFNAR1) as well as the intracellular signaling molecules Signal Transducers and Activator 
of Transcription (STAT)1 and STAT2. Besides IFN signaling genes, we also found a higher 
expression of many IFN target genes in carriers of the APOE4 SNP compared to non-carriers 
(Table 3 and Figure 3).  
To examine potential regulators of the observed gene expression differences between carriers 
and non-carriers, we performed Ingenuity upstream regulator analysis. IFNL1, IFNA2 and 
IFNG were identified as potential transcriptional regulators of the observed gene expression 
differences. These regulators and their targets are shown in Figure 3. Additionally, several 
other molecules that are involved in IFN signaling were identified as potential upstream 
regulators (Table 4). 
Fish-oil intervention effect 
To examine the effect of APOE4 on the gene expression response to fish-oil supplementation, 
we determined the genes that were differentially regulated in response to fish-oil 
supplementation in carriers compared to non-carriers of APOE4. We found that 866 genes 
showed a different change in expression caused by fish-oil supplementation between carriers 
and non-carriers at P < 0.05 (Figure 1). No genes showed an FDR q < 0.05.  
Figure 4 shows the enriched pathways when comparing the response to fish-oil 
supplementation between carriers and non-carriers of APOE4. The top 2 pathways are both 
related to IFN signaling. Furthermore, GSEA showed several gene sets related to IFN 
signaling as downregulated when comparing the response to fish-oil supplementation between 
carriers and non-carriers of APOE4 (Supporting Information table S5). 
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In carriers of the APOE4 allele, genes in these IFN signaling pathways were found to be 
mostly downregulated, whereas non-carriers mostly showed an upregulation in response to n-
3 PUFA supplementation when comparing gene expression after supplementation to 
expression at baseline.   
To examine potential regulators of the differentially expressed genes, we performed Ingenuity 
upstream regulator analysis. This revealed many IFN-related genes as potential upstream 
transcriptional regulators, including IFNL1, IFNA2 and IFNG (Table 5). The genes regulated 
by these cytokines were found to be largely downregulated in APOE4 carriers and largely 
upregulated in non-carriers, as shown in Figure 5.  
Comparison of gene expression profiles after 6 months fish-oil supplementation between 
carriers and non-carriers of APOE4 showed that both cholesterol biosynthesis as well as IFN 
signaling pathways were no longer enriched in the comparison between carriers and non-
carriers of APOE4 (data not shown). 
QPCR validation of the microarray findings 
QPCR was used to determine the expression of five genes selected from the cholesterol 
biosynthesis and IFN signaling pathways in all available RNA samples. We determined gene 
expression of HMGCR, HMGCS1, IFITM1, STAT1 and TAP1 in a total of 92 participants, of 
which 31 were APOE4 carriers and 61 were APOE4 non-carriers. We found that expression of 
HMGCS1 and STAT1 was significantly higher in APOE4 carriers compared to non-carriers at 
baseline (Figure 6). Mean expression of HMGCR, IFITM1 and TAP1 was higher in APOE4 
carriers compared to non-carriers, though these differences were not significant. 
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Discussion 
This study examined the effect of APOE4 on whole genome gene expression in PBMCs at 
baseline and in response to fish-oil supplementation. Expression of genes involved in 
cholesterol biosynthesis as well as IFN signaling and IFN target genes was found to be higher 
in APOE4 carriers compared to non-carriers. Interestingly, 6 months of fish-oil 
supplementation decreased IFN-related gene expression in APOE4 carriers.  
The increased expression of genes in the IFN signaling pathway and IFN-regulated genes in 
PBMCs of APOE4 carriers at baseline may point towards a systemic pro-inflammatory state. 
Consistent with our findings, APOE4 has been linked to increased systemic inflammation as 
carriers of the APOE4 allele have been shown to have higher plasma levels of the pro-
inflammatory cytokines IL-8 and TNF-α [26], and lower levels of the anti-inflammatory 
cytokine IL-10 [27]. Furthermore, IFNG produced by T-lymphocytes is highly expressed in 
atherosclerotic lesions and affects many processes involved in the pathogenesis of 
atherosclerosis [28]. Increased expression of genes in the IFN signaling pathway as well as 
increased expression of IFN targets in PBMCs of APOE4 carriers may unfavorably prime 
these cells and may increase the risk of atherosclerosis. The question remains whether the 
observed increase in IFN-related gene expression is caused by APOE4 directly, or whether it 
is a consequence of indirect factors that are affected by APOE4.  
Literature on the role of fish-oil or n-3 PUFAs on IFN pathways and IFN-regulated genes is 
scarce. It is possible that previous studies that did not take APOE genotype into account found 
no effects, as we show in the current study that IFN signaling-related gene expression is either 
upregulated or downregulated dependent on APOE genotype. We identified one mouse study, 
in which a high intake of n-3 PUFAs was shown to lead to diminished STAT1 
phosphorylation after ex-vivo stimulation of immune cells with IFN-gamma [29]. A similar 
mechanism could be present in our APOE4 carriers, though, to our knowledge, no studies 
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exist that have examined the role of APOE genotype in this context. One relatively small 
study in 35 Alzheimer’s disease patients examined the interaction between APOE genotype 
and 6 months of fish-oil supplementation on several inflammatory cytokines in the plasma, 
but found no effects of APOE genotype [30].  
In contrast to APOE4 carriers, non-carriers showed an upregulation of IFN pathways. 
Previously, we examined the effects of fish-oil supplementation in this population and found 
anti-inflammatory and anti-atherogenic gene expression changes when not taking APOE 
genotype into account [15]. These changes were not found in genes related to IFN signaling 
pathways. This indicates that fish-oil supplementation may have pro-inflammatory as well as 
anti-inflammatory effects in APOE4 non-carriers. Further research is required to fully 
understand the APOE genotype-specific effects of fish-oil supplementation on inflammatory 
signaling. 
APOE4 is associated with an increased risk of CVD [4]. Partly, this is thought to be mediated 
by increased LDL-cholesterol and triglyceride plasma concentrations in APOE4 carriers [31]. 
In the full study group of 301 participants, we also observed significantly higher LDL-
cholesterol levels in the plasma of APOE4 carriers compared to non-carriers. Our microarray 
data point towards an increase in cholesterol synthesis as reflected by a higher expression of 
several genes encoding enzymes involved in the synthesis of cholesterol, including HMG-
CoA reductase (HMGCR), the enzyme catalyzing the rate-limiting step in the synthesis of 
cholesterol [32]. Expression of this gene and other genes involved in cholesterol biosynthesis 
is known to be controlled by the SREBP-2 transcription factor through a negative feedback 
system [33]. Therefore, the higher expression of cholesterol biosynthesis genes in APOE4 
carriers might suggests a lower intracellular cholesterol concentration and, consequently, a 
reduced activity of SREBP-2. However, the SREBP-2 gene itself was not differentially 
expressed between APOE4 carriers and non-carriers and, based on the increased LDL-
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cholesterol concentrations in APOE4 carriers that we observed in the full study group of 301 
participants and is consistently reported in literature, one might expect increased intracellular 
cholesterol levels. Whether cholesterol levels are actually increased in the cell requires further 
investigation.  
The role of increased cholesterol synthesis in monocytes remains unclear.  It may promote 
cholesterol accumulation in these cells, which is an important first step in foam cell formation 
and may, therefore, potentially be related to the increased CVD risk in APOE4 carriers. 
Additionally, in a study by Gerdes et al. (2000) [34], treatment with simvastatin, an inhibitor 
of the HMGCR protein, abolishes the APOE4-related 2-fold increase in mortality after a 
previous myocardial infarction. This study indicates that persons carrying a copy of the 
APOE4 allele are especially sensitive to cholesterol synthesis altering interventions. HMGCR 
gene expression in PBMCs has been shown to closely parallel liver gene expression [35]. If 
the higher expression of this gene and other SREBP-2-regulated cholesterol biosynthesis 
genes is present in liver as well, it may possibly explain why APOE4 carriers are especially 
sensitive to cholesterol synthesis altering interventions with respect to CVD risk. 
In this study, we describe changes in two pathways that may potentially contribute to the 
increased CVD risk that is observed in carriers of APOE4: (1) increased expression of IFN 
signaling and IFN target genes, and (2) increased expression of cholesterol biosynthesis 
genes. Several studies have examined a possible link between inflammation and cholesterol 
synthesis. Chen et al. [36] found that inflammatory stress causes intracellular cholesterol 
accumulation, and increases HMGCR gene and protein expression via the SREBP-2 pathway 
in mice both in vitro as well as in vivo. Furthermore, Zhao et al. [37] induced inflammatory 
stress in mice and in a human cell line and found increased cholesterol synthesis and SREBP-
2 and HMGCR gene and protein expression. Taking these findings and our gene expression 
results together, it might be possible that increased inflammatory stress, as indicated by 
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increased IFN signaling in APOE4 carriers may have affected cholesterol biosynthesis gene 
expression. Further research is required, however, to explore the role of inflammatory stress 
and cholesterol biosynthesis as potential mechanisms for the increased CVD risk in APOE4 
carriers as well as the relationship between these processes.   
Although the expression of genes in the cholesterol biosynthesis pathway was significantly 
higher in APOE4 carriers compared to non-carriers, we did not observe a significant response 
to fish-oil supplementation in either group. When comparing carriers and non-carriers after 
supplementation the cholesterol biosynthesis pathway is no longer significantly differently 
expressed, suggesting that fish-oil might have affected gene expression of these genes to some 
extent. Possibly, these changes may have gone undetected due to the relatively low number of 
participants, especially in the APOE4 group.  
A limitation of this study is that, due to the fact that it was not originally designed to answer 
the current research question, the groups are relatively small and not of the same size. We 
performed power calculations, which showed that we had sufficient power for the microarray 
analyses. Distinct differences in gene expression between carriers and non-carriers of the 
APOE4 allele, both at baseline as well as in the response to a 6-month fish-oil intervention 
were observed. Furthermore, several of the differences at baseline were confirmed in a larger 
group using qPCR. For our microarray analyses, we used a relatively high P-value cut-off of 
0.05. Using FDR q-values for selecting the differentially expressed genes did not yield results 
in several comparisons. For this reason, we focused our analyses mainly on the pathway level. 
In this study, we opted not to include to placebo group in the analysis [15]. Firstly, because 
our study is focused on the differences between APOE4 carriers and non-carriers in the 
response to fish-oil. Secondly, adding this group, would further complicate this already quite 
complicated analysis and, as a consequence, reduce the readability of the paper. 
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The opposite effect of fish-oil supplementation in APOE4 carriers and non-carriers that we 
found, can partially explain the heterogeneity that is seen in the responses to fish-oil 
supplementation on gene expression profiles and illustrates the importance of research on 
diet-gene interactions and research into personalized nutrition in general. 
Our findings related to IFN signaling and cholesterol biosynthesis might explain part of the 
association between APOE4 and the increased risk of CVD that is observed in carriers of this 
allele. Additionally, with respect to our IFN signaling gene expression results we hypothesize 
that fish-oil supplementation may particularly benefit APOE4 carriers. 
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Figures and tables 
 
Figure 1. Flow chart of gene selection methods and number of significantly differentially 
expressed genes. Genes were found to be significantly different if P < 0.05. 
 
Figure 2. Top 10 differentially expressed pathways at baseline between APOE4 carriers and 
non-carriers. Top 10 was based on the lowest P-value. Total genes: total number of genes in 
the pathway, up (red): number of genes with significantly higher expression in APOE4 
carriers compared to non-carriers, down (green): number of genes with significantly lower 
expression in APOE4 carriers compared to non-carriers. 
 
Figure 3. Genes of which the expression is known to be regulated by IFNA2, IFNG and 
IFNL1 that are significantly differentially expressed at baseline in APOE4 carriers compared 
to non-carriers. Red indicates a significantly higher expression, green indicates a significantly 
lower expression (P <0.05). Orange arrow, gene is predicted to be activated by regulator; blue 
arrow, gene is predicted to be inhibited by regulator; yellow arrow, gene expression of 
downstream gene is inconsistent with predicted state. 
 
Figure 4. Top 10 pathways differentially regulated by fish-oil supplementation in APOE4 
carriers compared to non-carriers. The 10 canonical pathways with the lowest P-value are 
shown. The number of significantly up-regulated and down-regulated genes by fish-oil 
supplementation in APOE4 carriers and APOE4 non-carriers are shown. Total genes: total 
number of genes in the pathway, up (red): number of genes with significantly higher 
expression after intervention compared to before, down (green): number of genes with 
significantly lower expression after intervention compared to before. 
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Figure 5. Heatmap depicting individual gene expression changes by fish-oil supplementation 
of genes that are significantly differently changed between carriers and non-carriers of 
APOE4 in response to fish-oil supplementation and are known to be regulated by IFNL1, 
IFNA2 and IFNG. Log-ratios of the expression after and before supplementation are shown.  
 
Figure 6. QPCR results of a selection of genes showing the log ratio of expression in APOE4 
carriers compared to non-carriers. Values are mean ± SEM. * p<0.05 in carriers compared to 
non-carriers. 
HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HMGCS1, 3-hydroxy-3-
methylglutaryl-CoA synthase 1; IFITM1, IFN induced transmembrane protein 1; STAT1, 
signal transducer and activator of transcription 1; TAP1, transporter 1, ATP-binding cassette, 
sub-family B.  
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Table 1. Primer sequences used to quantify gene expression by qPCR. 
Gene Forward primer Reverse Primer 
HMGCR TGATTGACCTTTCCAGAGCAAG CTAAAATTGCCATTCCACGAGC 
HMGCS1 CAGAAGAACTTACGCTCGGC TCTTGGCAGGGCTTGGAATA 
IFITM1 AGGGACAGGAAGATGGTTGG AATCAGGGCCCAGATGTTCA 
RPLP0 CAGATTGGCTACCCAACTGTT GGGAAGGTGTAATCCGTCTCC 
STAT1 GAGAGTCTGCAGCAAGTTCG GGAAAAGACTGAAGGTGCGG 
TAP1 ATTTGAGTACCTGGACCGCA GCCCCTGTAGCACTAAGACA 
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Table 2. Baseline characteristics of the 23 participants of the high fish-oil supplementation 
group in which PBMC gene expression microarrays were performed.
a
 
 APOE4 carriers (N=8) APOE4 non-carriers (N=15) 
Age 69 ± 3 69 ± 3 
M/F 5/3 10/5 
M/F % 62/38 67/33 
Heigth (cm) 170 ± 8 173 ± 6 
Weight (kg) 77 ± 7 78 ± 14 
BMI (kg/m
2
) 27.1 ± 3.0 26.1 ± 3.4 
Waist circumference (cm) 96 ± 6 96 ± 14 
Total cholesterol (mmol/l) 6.0 ± 0.6 5.4 ± 0.9 
Triglycerides (mmol/l) 1.2 ± 0.2 0.9 ± 0.4 
LDL-cholesterol (mmol/l) 4.1 ± 0.5 3.5 ± 0.8 
HDL-cholesterol (mmol/l) 1.5 ± 0.4 1.5 ± 0.3 
hsCRP  (mg/L)
b
 2.0 ± 1.9 3.3 ± 3.2 
 
a
 Data presented as mean ± sd. Baseline values were not significantly different between 
carriers and non-carriers at P < 0.05.  
b
 hsCRP, high sensitivity C-reactive protein.  
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Table 3. Baseline comparison of APOE4 carriers and non-carriers of genes involved in 
cholesterol biosynthesis, IFN signaling and IFN targets.
 a
 
 
Gene 
Entrez 
ID Description P-value
 b
 Fold change  
Cholesterol synthesis  
   
 DHCR24 1718 24-dehydrocholesterol reductase 0.02 1.24 
 GGPS1 9453 geranylgeranyl diphosphate synthase 1 0.05 1.21 
 HADHA 3030 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), alpha subunit <0.01 -1.12 
 HADHB 3032 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit 0.04 -1.08 
 HMGCR 3156 3-hydroxy-3-methylglutaryl-CoA reductase 0.02 1.24 
 HMGCS1 3157 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) <0.01 1.18 
 IDI1 3422 isopentenyl-diphosphate delta isomerase 1 <0.01 1.14 
IFN signaling     
 IFNAR1 3454 interferon (alpha, beta and omega) receptor 1 <0.01 1.26 
 IRF9 10379 interferon regulatory factor 9 <0.01 1.26 
 MX1 4599 MX dynamin-like GTPase 1 0.02 1.73 
 PSMB8 5696 proteasome (prosome, macropain) subunit, beta type, 8 <0.01 1.13 
IFN targets     
 IFI35 3430 interferon-induced protein 35 0.01 1.33 
 IFIT1 3434 interferon-induced protein with tetratricopeptide repeats 1 <0.01 2.54 
 IFIT3 3437 interferon-induced protein with tetratricopeptide repeats 3 0.01 2.01 
 IFITM1 8519 interferon induced transmembrane protein 1 <0.01 1.17 
 IFNAR1 3454 interferon (alpha, beta and omega) receptor 1 <0.01 1.26 
 IRF9 10379 interferon regulatory factor 9 <0.01 1.26 
 MX1 4599 MX dynamin-like GTPase 1 0.02 1.73 
 
a
 Genes selection is based on Ingenuity canonical pathways.  
b
 P-values and fold changes for the comparison between APOE4 carriers and non-carriers are 
shown. P-values were considered significant when P < 0.05. 
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Table 4. Top 10 potential upstream regulators
a
 explaining the baseline differences in gene 
expression between APOE4 carriers and non-carriers.
b
 
Upstream Regulator Fold Change Molecule Type Predicted Activation State Activation z-score P-value of overlap 
PRL -1.17 cytokine Activated 6.76 3.77E-33 
IFNL1 1.02 cytokine Activated 6.21 2.14E-29 
IFNA2 -1.03 cytokine Activated 6.17 3.06E-23 
MAPK1 -1.02 kinase Inhibited -6.13 2.13E-18 
CNOT7 1.03 transcription regulator Inhibited -2.43 1.31E-15 
IL1RN 1.13 cytokine Inhibited -4.64 1.89E-15 
IFNG 1.32 cytokine Activated 5.45 5.33E-12 
EIF2AK2 1.49 kinase Activated 3.75 1.92E-09 
Interferon alpha   group Activated 4.01 2.90E-08 
IFNB1   cytokine Activated 3.44 1.86E-06 
 
a
 Ingenuity upstream regulator analysis identifies transcriptional regulators that can potentially 
explain the observed changes in gene expression.  
b
 The 10 regulators with the lowest P-value and a significant Z score are shown. Fold change 
for the upstream regulator is shown if significantly differentially expressed. Z scores predict 
the activation state of the regulator and are based on the gene expression of its downstream 
genes. Upstream regulators with z scores > 2 are considered activated and regulators with z 
scores < 2 are considered inhibited. P-values of overlap are calculated using Fisher’s exact 
test. 
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Table 5. Top 10 potential upstream regulators
a
 identified for the difference in gene expression 
changes in response to 6 months of fish-oil supplementation between carriers and non-carriers 
of the APOE4 SNP.
 b
 
  
Difference in 
response to fish-oil Response in APOE4 carriers Response in APOE4 non-carriers 
Regulator Molecule Type P-value 
Activation 
state Z score P-value Activation state Z score P-value 
PRL cytokine 4.09E-39 Inhibited -4.59 2.90E-20   1.92 1.89E-03 
IFNL1 cytokine 2.31E-30 Inhibited -4.53 5.84E-11 Activated 3.50 1.18E-03 
IFNA2 cytokine 2.98E-28 Inhibited -5.01 1.67E-15 Activated 2.36 1.71E-04 
MAPK1 kinase 2.24E-23 Activated 5.77 3.44E-15 Inhibited -3.93 7.55E-03 
CNOT7 transcription regulator 2.87E-19 Activated 2.22 2.13E-08   Not significant 
IL1RN cytokine 4.34E-19 Activated 3.30 3.31E-08 Inhibited -2.52 4.69E-03 
IFNG cytokine 2.80E-17 Inhibited -3.97 7.67E-13 Inhibited -2.52 4.69E-03 
TGM2 enzyme 3.11E-13 Inhibited -4.65 1.18E-13 Inhibited -2.12 1.05E-06 
EIF2AK2 kinase 3.30E-13 Inhibited -3.71 8.84E-06   0.31 2.72E-02 
STAT2 transcription regulator 2.59E-12     1.47E-05     2.17E-02 
 
a
 Ingenuity upstream regulator analysis identifies transcriptional regulators that can potentially 
explain the observed changes in gene expression.  
b
 The 10 regulators with the lowest P-value and a significant Z score are shown for the 
difference in gene expression changes in response to 6 months of fish-oil supplementation 
between APOE4 carriers and non-carriers are shown. Z scores, activation state and p-values 
are depicted for the responses within the groups of APOE4 carriers and the non-carriers. Z 
scores predict the activation state of the regulator and are based on the gene expression of its 
downstream genes. Upstream regulators with z scores > 2 are considered activated and 
regulators with z scores < 2 are considered inhibited. P-values of overlap are calculated using 
Fisher’s exact test. 
